The executive order sets a 90-day deadline and replaces a Biden-era initiative. It does not name a budget. WASHINGTON, 19 October 2026. President Donald Trump signed an executive order on Monday directing the National Institutes of Health (NIH) to create a new NIH Women’s Health Division within 90 days. The order, titled “Advancing Women’s Health to Improve Outcomes in All Phases of Life,” also creates a White House Women’s Health Task Force. You can read the full text on the White House website. The order says it must be carried out “subject to the availability of appropriations,” and it sets no dollar amount. Details are based on the order’s text and the HHS announcement. Independent reaction was still limited at the time of writing.
What the NIH Women’s Health Division Order Does
The order says women’s health conditions have not received the same research attention as other diseases. It lists heart disease, cancer, stroke, Alzheimer’s disease, autoimmune conditions, osteoporosis, mental health, chronic pain, endometriosis, fibroids, infertility, maternal health and menopause among the areas needing more work. It says the goal is to move research into clinical care faster.
The order does two main things. It orders a new division inside the NIH, the main US government funder of medical research, and it sets up a task force across the executive branch. It also cancels two Biden-era actions on the same subject, which is covered below.
How the NIH Women’s Health Division Would Work
The Health and Human Services (HHS) secretary, acting through the NIH director, must set up the NIH Women’s Health Division within 90 days. By our count, that deadline falls around 17 January 2027. The order says it should sit inside “an appropriate institute or center” and work with the existing NIH Office of Research on Women’s Health.
The division’s tasks include:
- reviewing women’s health conditions that remain understudied
- supporting replication studies, which test whether earlier findings hold up
- improving data collection and including more women and girls in clinical trials
- holding grant recipients accountable for following the NIH policy on considering sex as a biological variable
- speeding up the move from lab findings to clinical practice
HHS Secretary Robert F. Kennedy Jr. said the division would tackle unanswered questions “with gold-standard science.” NIH Director Jay Bhattacharya said it should help close evidence gaps and bring discoveries closer to patients.
The White House Task Force and NIH Women’s Health Division Integration
The new White House Women’s Health Task Force will be co-chaired by Kennedy and White House Chief of Staff Susie Wiles. Members include the heads of Agriculture, Labor, Education, Veterans Affairs and War, along with the EPA administrator and the leaders of the FDA, CDC, NIH, ARPA-H and Medicare and Medicaid. The task force can hold hearings and roundtables, and HHS will pay its administrative costs.
Its remit is wide. It is to coordinate federal work on women’s health from childhood through pregnancy, midlife, menopause and aging, and to push for evidence-based care across primary care, specialty care and behavioural health. It will also consult states, tribal nations, community groups and the private sector.
What the Executive Order Revokes and Leaves Out
The order revokes Executive Order 14120, signed in March 2024, which was titled “Advancing Women’s Health Research and Innovation.” It also revokes a November 2023 presidential memorandum creating a White House initiative on women’s health research. The HHS announcement describing the new order does not mention that either was cancelled.
The order also leaves several things unspecified. It gives no budget for the new division, no staffing numbers and no target for clinical trial enrolment. How the new division would differ in practice from the existing NIH Office of Research on Women’s Health is not spelled out.
Why Research Gaps Addressed by the NIH Women’s Health Division Matter
For decades, most medical studies were done on men, which left questions about women’s health unanswered. The NIH launched the Women’s Health Initiative in the early 1990s partly to address that. Today it follows tens of thousands of participants.
The administration’s own record has drawn scrutiny. In April 2025, HHS moved to end contracts for the Women’s Health Initiative’s regional centres, then reversed course within days. An HHS spokesperson said the NIH had “initially exceeded its internal targets for contract reductions.” In a June 2026 letter, leaders of the House Democratic Women’s Caucus accused the administration of undermining women’s health research. HHS says it has expanded work on menopause, maternal health, infertility and breast cancer screening since January 2025. These are the department’s own descriptions of its record.
Who is Affected by the NIH Women’s Health Division
- Documented: The order directs the changes above. Whether it changes funding or care depends on later decisions.
- Reported by officials: HHS says earlier actions have included new menopause drug approvals and a national breast cancer screening initiative. That is an agency claim and has not been independently assessed here.
- Likely, if carried out and funded: More attention to conditions such as endometriosis, fibroids and menopause, and better evidence for clinicians and patients over time. These effects would take years to show up.
- Unknown: How much money the division will have, who will lead it, and whether it will change what the NIH funds.
This article reports on a policy decision and is not medical advice.
What to Watch Next for the NIH Women’s Health Division
The first deadline falls in mid-January 2027, when the NIH Women’s Health Division is due to exist. Before then, watch for the division’s leadership, its budget and where it sits within the NIH. Researchers and patient groups will be looking for whether the order brings new funding or mainly restructures existing work. For more international coverage, visit Human Crisis News.